The estimated Net Worth of Raphael Rousseau is at least $1.1 Millón dollars as of 27 May 2021. Raphael Rousseau owns over 2,900 units of Gritstone Bio Inc stock worth over $1,421 and over the last 6 years he sold GRTS stock worth over $0. In addition, he makes $1,099,810 as Executive Vice President y Chief Medical Officer at Gritstone Bio Inc.
Raphael has made over 3 trades of the Gritstone Bio Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 2,900 units of GRTS stock worth $2,204 on 27 May 2021.
The largest trade he's ever made was exercising 30,000 units of Gritstone Bio Inc stock on 19 January 2021 worth over $22,800. On average, Raphael trades about 6,129 units every 92 days since 2019. As of 27 May 2021 he still owns at least 2,900 units of Gritstone Bio Inc stock.
You can see the complete history of Raphael Rousseau stock trades at the bottom of the page.
Dr. Raphael F. Rousseau M.D. Ph.D. serves as Executive Vice President, Chief Medical Officer of the Company. He has served as our Executive Vice President, Chief Medical Officer since April 2017. Prior to Gritstone, from July 2012 to March 2017, Dr. Rousseau served as senior group medical director and global franchise head, pediatrics of Genentech. Before Genentech, Dr. Rousseau was senior medical director and lead of the pediatric global development team at Roche from October 2010 to June 2012, and international medical leader, hematology, at Roche from January 2009 to September 2010. Before joining Roche, Dr. Rousseau was a professor of medical and pediatric oncology at the Université Claude Bernard in Lyon, France. At the Léon Bérard Comprehensive Cancer Center in Lyon, Dr. Rousseau was head of the pediatric translational research program. Earlier in his career, he was a clinical fellow at Texas Children’s Cancer Center and a research fellow at the Center for Cell and Gene Therapy at Baylor College of Medicine in Houston. He received a Ph.D. in therapeutic biotechnologies at the Université Denis Diderot and an M.D. from Université René Descartes, both in Paris. He is board certified in pediatrics and has a sub-specialty certification in pediatric hematology-oncology.
As the Executive Vice President y Chief Medical Officer of Gritstone Bio Inc, the total compensation of Raphael Rousseau at Gritstone Bio Inc is $1,099,810. There are 2 executives at Gritstone Bio Inc getting paid more, with Andrew Allen having the highest compensation of $2,187,440.
Raphael Rousseau is 51, he's been the Executive Vice President y Chief Medical Officer of Gritstone Bio Inc since 2017. There are 8 older and 9 younger executives at Gritstone Bio Inc. The oldest executive at Gritstone Bio Inc is Alan C. Mendelson J.D., 71, who is the Sec..
Raphael's mailing address filed with the SEC is C/O GRITSTONE BIO, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE, CA, 94608.
Over the last 6 years, insiders at Gritstone Bio Inc have traded over $277,077 worth of Gritstone Bio Inc stock and bought 2,026,375 units worth $15,022,790 . The most active insiders traders include Group, Llc Green Jeremy Red..., Peter Svennilson y Thomas Woiwode. On average, Gritstone Bio Inc executives and independent directors trade stock every 103 days with the average trade being worth of $54,654. The most recent stock trade was executed by Andrew R Allen on 15 May 2024, trading 24,263 units of GRTS stock currently worth $18,197.
gritstone oncology is a cancer immunotherapy company developing next-generation personalized cancer therapeutics. gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and very deep financial backing to tackle fundamental challenges at the intersection of cancer biology, immunology, and immunotherapy design. the company’s initial goal is to identify and deploy therapeutic neo-antigens from individual patients’ tumors to develop novel treatments for lung cancer. gritstone oncology is headquartered in the san francisco bay area with certain key functions located in cambridge, ma. gritstone oncology launched in october 2015 with a series a financing of $102 million.
Gritstone Bio Inc executives and other stock owners filed with the SEC include: